Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas
other
OA: hybrid
CC-BY-4.0
AI-generated summary
Whole exome sequencing demonstrated genomic relatedness between paired non-serous endometrial and ovarian carcinomas in all 27 patients studied, supporting a common origin hypothesis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
INTRODUCTION: Concurrent non-serous endometrial and ovarian tumours are often managed clinically as two separate primary tumours, but almost all exhibit evidence of a genomic relationship.
METHODOLOGY: This study investigates the extent of relatedness using whole exome sequencing, which was performed on paired non-serous endometrial and ovarian carcinomas from 27 patients with concurrent tumours in a cohort with detailed clinicopathological annotation. Four whole exome sequencing-derived parameters (mutation, mutational burden, mutational signatures and mutant allele tumour heterogeneity scores) were used to develop a novel unsupervised model for the assessment of genomic similarity to infer genomic relatedness of paired tumours.
RESULTS: This novel model demonstrated genomic relatedness across all four parameters in all tumour pairs. Mutations in PTEN, ARID1A, CTNNB1, KMT2D and PIK3CA occurred most frequently and 24 of 27 (89 %) tumour pairs shared identical mutations in at least one of these genes, with all pairs sharing mutations in a number of other genes. Ovarian endometriosis, CTNNB1 exon 3 mutation, and progression and death from disease were present across the similarity ranking. Mismatch repair deficiency was associated with less genomically similar pairs.
DISCUSSION: Although there was diversity across the cohort, the presence of genomic similarity in all paired tumours supports the hypothesis that concurrent non-serous endometrial and ovarian carcinomas are genomically related and may have arisen from a common origin.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Funding
- funders
- [{'doi': '10.13039/501100000672', 'name': 'Pathological Society of Great Britain and Ireland', 'awards': []}, {'doi': '10.13039/501100000289', 'name': 'Cancer Research UK', 'awards': []}, {'doi': '10.13039/501100008171', 'name': 'Target Ovarian Cancer', 'awards': []}, {'doi': '10.13039/100015654', 'name': 'Nicola Murray Foundation', 'awards': []}]
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (45)
- Cancer-Associated Mutations in Endometriosis without Cancer via crossref
- Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? via crossref
- Clear cell carcinoma of the ovary: a clinical and molecular perspective via crossref
- Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. via crossref
- <i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas via crossref
- Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome. via crossref
- Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. via crossref
- Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. via crossref
- Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles via crossref
- Synchronous carcinomas of endometrium and ovary: A pragmatic approach. via crossref
- The Evolution of Ovarian Carcinoma Subclassification. via crossref
- The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas. via crossref
- doi:10.1101/gr.107524.110 via crossref
- doi:10.1093/nar/gkw227 via crossref
- doi:10.1038/nbt.2514 via crossref
- doi:10.1016/j.gim.2022.01.001 via crossref
- doi:10.1101/gr.239244.118 via crossref
- doi:10.1016/j.cell.2018.03.035 via crossref
- doi:10.1093/nar/gky1015 via crossref
- doi:10.1186/s13059-016-0893-4 via crossref
- doi:10.1016/j.oraloncology.2012.09.007 via crossref
- doi:10.1097/igc.0000000000000492 via crossref
- doi:10.1158/1078-0432.ccr-08-0373 via crossref
- doi:10.1016/j.ygyno.2019.09.001 via crossref
- doi:10.1093/pcmedi/pbaa019 via crossref
- doi:10.1200/jco.2014.56.7644 via crossref
- doi:10.1186/s13073-022-01083-1 via crossref
- doi:10.1016/j.ygeno.2014.07.012 via crossref
- doi:10.1016/j.ejogrb.2006.09.010 via crossref
- doi:10.1097/pas.0000000000001478 via crossref
- doi:10.1158/1078-0432.ccr-20-1268 via crossref
- doi:10.1136/ijgc-2020-001822 via crossref
- doi:10.1007/s00404-021-06385-0 via crossref
- doi:10.1016/j.ygyno.2020.02.011 via crossref
- doi:10.1007/s00404-008-0800-7 via crossref
- doi:10.1111/j.1365-2559.2009.03367.x via crossref
- doi:10.1111/jog.12826 via crossref
- doi:10.1097/igc.0000000000000971 via crossref
- doi:10.1111/his.13985 via crossref
- doi:10.1038/nature12113 via crossref
- doi:10.1002/cncr.30496 via crossref
- doi:10.1093/annonc/mdy058 via crossref
- doi:10.1038/s41698-021-00187-y via crossref
- doi:10.1097/pas.0000000000001553 via crossref
- doi:10.1111/1471-0528.16264 via crossref
Source provenance
- crossref
- last seen: 2026-07-02T06:26:54.156689+00:00
- europepmc
- last seen: 2026-09-21T06:08:07.822426+00:00
- pubmed
- last seen: 2026-09-21T06:06:15.870345+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: CC-BY-4.0
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine